Table 5.
Probability of AKI increases with incorporation of biomarkers into the RAI
| RAI | Ela-2 | MMP-8 | NGAL | AKI Probability (%) |
|---|---|---|---|---|
| − | − | a | a | 0 |
| − | + | a | a | 5 |
| + | − | a | a | 5.3 |
| + | + | a | a | 27.3 |
| − | a | − | a | 0 |
| − | a | + | a | 4.3 |
| + | a | − | a | 4.9 |
| + | a | + | a | 24.1 |
| − | a | a | − | 0 |
| − | a | a | + | 4.4 |
| + | a | a | − | 6.8 |
| + | a | a | + | 23.8 |
| − | − | − | a | 0 |
| − | − | + | a | 0 |
| − | + | − | a | 0 |
| − | + | + | a | 7.4 |
| + | − | − | a | 0 |
| + | − | + | a | 8.8 |
| + | + | − | a | 11.1 |
| + | + | + | a | 31.4 |
The probability of day 3 AKI, determined as a percentage of patients with AKI in a given biomarker delineated subpopulation is shown for each biomarker profile. Individual rates and patient flow maps are depicted in Supplemental Material C.
a
Biomarker not included for the particular analysis.